Moreover, CCL2 siRNA could significantly inhibit the production of CXCL1, IL-1β, IL-17A, IL-18, and IL-6 by NMO-IgG stimulation and significantly improves the cellular inflammatory status (Figure 4H). The gene discussed is CCL2; the disease is neuromyelitis optica.